利塞膦酸钠对绝经后骨质疏松症患者血BGP及尿NTX/Cr的影响  

Effects of risedronate sodium on serum BGP and urine NTX/Cr in patients with postmenopausal osteoporosis

作　　者：周日[1] 刘建[1] 孟国林[1] 

机构地区：[1]第四军医大学西京医院骨科,陕西西安710033

出　　处：《第四军医大学学报》2009年第7期649-651,共3页Journal of the Fourth Military Medical University

摘　　要：目的:利塞膦酸钠胶囊治疗绝经后骨质疏松症(PMOP)患者,观察血骨钙素(BGP)和尿Ⅰ型胶原氨基末端肽/肌酐(NTX/Cr)的变化并探讨其意义.方法:受试者120对随机等分入利塞膦酸钠组(A组)和安慰剂组(B组).A组给予利塞膦酸钠胶囊+碳酸钙D3咀嚼片,B组给予安慰剂+碳酸钙D3咀嚼片.整个试验疗程为12mo,在治疗前、用药后6mo及12mo随访,分别采用放射免疫测定法(RIA)和酶联免疫吸附剂测定(ELISA)法检测BGP和NTX(nmol/L)/Cr(mmol/L)值.结果:BGPA组下降了(2.9±4.7)μg/L,B组下降了(0.5±3.9)μg/L.NTX/CrA组下降了(9.4±65.9),B组升高了(3.6±59.9).两组比较差异均有统计学意义(P<0.05).结论:利塞膦酸钠胶囊能够有效抑制PMOP患者的骨吸收,降低骨转换.AIM： To study the effects of Risedronate Sodium Capsules on serum BGP and urine NTX/Cr in patients with postmenopausal osteoporosis （PMOP）. METHODS ： One hundred and twenty pairs of postmenopausal women with low bone mineral density（ BMD ） were randomly classified into 2 groups. Group A （n = 120） were treated by risedronate sodium, 5 mg, q. d with calcium 0.5 g and vitamin D 200 IU, q.d. and Group B（ n = 120） received the same treatment as that in group A except that placebo was given instead of risedronate sodium. The duration of the study was set to 12 months. Serum bone gla protein（BGP） and urine crosslinked N-telopeptide of collagen typeI/ereatine （NTX/Cr） were determined before as well as 6 and 12 months after the treatment by radioimmunoassay （RIA） and enzyme-linked immunosorbent assay （ELISA）. RESULTS： At the end of the treatment, BGP decreased by （2.9 ± 4.7 ） and （ 0.5 ± 3.9 ） μg/L respectively in group A and group B. In group A, NTX （nmol/L）/Cr （retool/L） decreased by（9.4 ±65.9） but increased by（3.6 ± 59.9 ） in group B. There was statistical difference in BGP and NTX/Cr between the 2 groups. CONCLUSION： Risedronate sodium inhibits bone absorption and decreases bone turnover in women with postmenopausal osteoporosis.

关 键 词：利塞膦酸钠 骨质疏松 骨代谢指标 

分 类 号：R453.9[医药卫生—治疗学] R681.1[医药卫生—临床医学]